We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Density and maturity of peritumoral tertiary lymphoid structures in oesophageal squamous cell carcinoma predicts patient survival and response to immune checkpoint inhibitors.
- Authors
Hayashi, Yoshinori; Makino, Tomoki; Sato, Eiichi; Ohshima, Kenji; Nogi, Yuya; Kanemura, Takashi; Honma, Keiichiro; Yamashita, Kotaro; Saito, Takuro; Tanaka, Koji; Yamamoto, Kazuyoshi; Takahashi, Tsuyoshi; Kurokawa, Yukinori; Miyata, Hiroshi; Nakajima, Kiyokazu; Wada, Hisashi; Morii, Eiichi; Eguchi, Hidetoshi; Doki, Yuichiro
- Abstract
Background: Tertiary lymphoid structures (TLSs) are ectopic lymphoid aggregates in non-lymphoid tissues, which are associated with improved prognosis in some cancer types. This study aimed to investigate the clinical significance of TLSs in oesophageal cancer (EC). Methods: In a series of 316 EC surgical specimens from two different institutes, we evaluated the density and maturity of peritumoral TLSs using haematoxylin/eosin, immunohistochemistry, and multiplex immunofluorescence staining. We analysed the association between TLSs and clinicopathological parameters. The clinical significance of TLSs was further evaluated in a different cohort of 34 patients with recurrent EC treated with anti-PD-1 antibody. Results: Tumours with high TLS density predominantly consisted of matured TLSs. High TLS density was significantly associated with less advanced tumour stage, absence of lymphatic/vascular invasion, better serum nutrition parameters (neutrophils count, albumin, neutrophil-to-lymphocyte ratio, and prognostic nutritional index), and prolonged survival. This survival trend was more remarkable in cases with matured TLSs, which represented an increased population of CD138+ plasma cells. In the second EC cohort, TLS density predicted the clinical response to anti-PD-1 antibody and patient survival. Conclusion: The density and maturity of peritumoral TLSs are useful parameters for predicting long-term survival and response to anti-PD-1 antibody treatment in EC patients.
- Publication
British Journal of Cancer, 2023, Vol 128, Issue 12, p2175
- ISSN
0007-0920
- Publication type
Article
- DOI
10.1038/s41416-023-02235-9